At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 23 enrolled
Drug / intervention
Voriconazole +1 moredrug
Likely dose
Voriconazole 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Kinetics of 1, 3 Beta-d- Glucan Assay in Patients With Hematologic Malignancies Receiving Voriconazole Prophylaxis
In Brief
A Phase 3 clinical trial evaluating Voriconazole for Leukemia and Fungal Infection. Completed, enrolled 23 participants across 1 site.
Detailed Summary
Objectives: To investigate the relationship between the administration of intravenous (IV) and oral voriconazole (vori) and the occurrence of false positive (1,3) beta-d- glucan (BG) relative to the standard assessment criteria used to diagnose invasive fungal infection in patients with hematologic malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Fungal Infection
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedMay 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedMay 20, 2009
Enrollment StartMay 1, 2009
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.1 years ago
Interventions
Voriconazoledrug
Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
Voriconazoledrug
6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.